Reason for request
Re-assessment of the actual benefit of third-generation oral contraceptives in response to a request by the Directorate-General for Health dated 27 December 2011.
Clinical Benefit
| Insufficient |
taking into account both the increased risk of venous thromboembolic events and the lack of demonstrated benefit in terms of clinical safety in women exposed to third-generation oral contraceptives compared with second- or first-generation oral contraceptives, the actual benefit of these proprietarymedicinal products must be regarded as insufficient for reimbursement by National Health Insurance. |
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
UhjncZggAGPCdQ4E
